Search Results - "Mangan, Brendan L"

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide by Mangan, Brendan L., Patel, Dilan, Chen, Heidi, Gatwood, Katie S., Byrne, Michael T., Sengsayadeth, Salyka, Goodman, Stacey, Dholaria, Bhagirathbhai, Kassim, Adetola A., Jagasia, Madan, Chinratanalab, Wichai, Culos, Kathryn A., Engelhardt, Brian G.

“…Haploidentical hematopoietic cell transplantation (haplo‐HCT) with posttransplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders…”
Get full text

Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy by Mangan, Brendan L., McAlister, Renee K., Balko, Justin M., Johnson, Douglas B., Moslehi, Javid J., Gibson, Andrew, Phillips, Elizabeth J.

“…Immune checkpoint inhibitors have emerged as a revolutionary treatment option for patients with various types of malignancy. Although these agents afford a…”
Get full text

Tailoring Therapy in Older Adults With Hematologic Malignancies by Mangan, Brendan L, DuMontier, Clark, Hopkins, Judith O, Abel, Gregory A, McCurdy, Shannon R

“…Hematologic malignancies most often present in the sixth or seventh decade of life. Even so, many older adults may be unable to tolerate standard chemotherapy…”
Get more information

Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia by Graveno, Molly E., Carulli, Alison, Freyer, Craig W., Mangan, Brendan L., Nietupski, Robert, Loren, Alison W., Frey, Noelle V., Porter, David L., Gill, Saar I., Hexner, Elizabeth O., Luger, Selina M., Martin, Mary Ellen, McCurdy, Shannon R., Perl, Alexander E., Babushok, Daria V., Pratz, Keith W.

“…Limited treatment options exist for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Venetoclax (VEN) in combination with a…”
Get full text

Evaluating the Clinical Benefit of Post-Transplant DNA Methyltransferase Inhibitor (DNMTi) Maintenance in MDS/AML by Orton, Lindsay, Gatwood, Katie S., Jayani, Reena V, Dholaria, Bhagirathbhai, Mangan, Brendan L., Chen, Heidi, Kim, Tae Kon, Savani, Bipin, Kassim, Adetola A., Engelhardt, Brian G., Byrne, Michael, Culos, Kathryn A.

Get full text

New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide by Mangan, Brendan L, Patel, Dilan, Chen, Heidi, Gatwood, Katie S, Byrne, Michael T, Sengsayadeth, Salyka, Goodman, Stacey, Dholaria, Bhagirathbhai, Kassim, Adetola A, Jagasia, Madan, Chinratanalab, Wichai, Culos, Kathryn A, Engelhardt, Brian G

“…Haploidentical hematopoietic cell transplant (haplo-HCT) with post-transplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but…”
Get full text

Inferior Outcomes for Patients Developing New-Onset Post-Transplant Diabetes Mellitus after Haploidentical Hematopoietic Cell Transplant by Mangan, Brendan L., Patel, Dilan A., Chen, Heidi, Gatwood, Katie S., Byrne, Michael T., Sengsayadeth, Salyka, Goodman, Stacey, Dholaria, Bhagirathbhai, Kassim, Adetola A., Jagasia, Madan, Savani, Bipin, Chinratanalab, Wichai, Cornell, Robert F., Engelhardt, Brian G., Culos, Kathryn Ann A.

“…The mortality rate triples for the 50% of patients diagnosed with new-onset post-transplant diabetes mellitus (PTDM) after HLA-identical allogeneic…”
Get full text